Monoclonal antobodies, benign breast disease, and breast cancer. A panel discussion

W. L. McGuire, R. L. Ceriani, J. Schlom, A. E. Frankel

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Hybridoma technology has now advanced to the point where hundreds of monoclonal antibodies have been produced and are reported to bind to normal and malignant cell surfaces or intracellular organelles. The original hope for tumor-specific antigens has not materialized, but certain antibodies with rather restricted ranges of binding activities have been indentified. This panel discusses the use of such monoclonal antibodies in diagnosis, prognosis, and treatment of human breast disease and breast cancer.

Original languageEnglish (US)
Pages (from-to)37-47
Number of pages11
JournalBreast Cancer Research and Treatment
Volume6
Issue number1
DOIs
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Monoclonal antobodies, benign breast disease, and breast cancer. A panel discussion'. Together they form a unique fingerprint.

  • Cite this